Sionna Therapeutics (NASDAQ:SION) Director Sells $38,928.75 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock in a transaction on Friday, December 19th. The stock was sold at an average price of $44.49, for a total value of $38,928.75. Following the sale, the director directly owned 3,595,011 shares of the company’s stock, valued at approximately $159,942,039.39. This trade represents a 0.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $4,449.00.
• On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.50, for a total value of $40,050.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Stock Down 4.2%

NASDAQ:SION traded down $1.84 during trading hours on Friday, hitting $42.37. The stock had a trading volume of 1,954,673 shares, compared to its average volume of 270,007. The business’s 50 day moving average is $38.54 and its 200-day moving average is $27.05. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently bought and sold shares of the company. Siren L.L.C. acquired a new stake in shares of Sionna Therapeutics in the first quarter valued at approximately $3,400,000. Zimmer Partners LP bought a new position in Sionna Therapeutics in the first quarter valued at $2,484,000. Goldman Sachs Group Inc. acquired a new stake in Sionna Therapeutics in the 1st quarter valued at $667,000. Alyeska Investment Group L.P. bought a new stake in Sionna Therapeutics during the 1st quarter worth about $1,948,000. Finally, Prudential Financial Inc. lifted its position in Sionna Therapeutics by 114.6% during the 2nd quarter. Prudential Financial Inc. now owns 135,185 shares of the company’s stock worth $2,345,000 after buying an additional 72,185 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st. Raymond James Financial reissued a “strong-buy” rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday. Finally, BTIG Research began coverage on shares of Sionna Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $50.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.